GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Qualis Innovations Inc (OTCPK:QLIS) » Definitions » 3-Year FCF Growth Rate

Qualis Innovations (Qualis Innovations) 3-Year FCF Growth Rate : 96.10% (As of Dec. 2023)


View and export this data going back to 2006. Start your Free Trial

What is Qualis Innovations 3-Year FCF Growth Rate?

Qualis Innovations's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 96.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 94.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 9 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Qualis Innovations was 96.60% per year. The lowest was 78.40% per year. And the median was 95.70% per year.


Competitive Comparison of Qualis Innovations's 3-Year FCF Growth Rate

For the Medical Devices subindustry, Qualis Innovations's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Qualis Innovations's 3-Year FCF Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Qualis Innovations's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Qualis Innovations's 3-Year FCF Growth Rate falls into.



Qualis Innovations 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Qualis Innovations  (OTCPK:QLIS) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Qualis Innovations 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Qualis Innovations's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Qualis Innovations (Qualis Innovations) Business Description

Traded in Other Exchanges
N/A
Address
225 Wilmington West Chester Pike, Suite 200, No.145, Chadds Ford, PA, USA, 19317
Qualis Innovations Inc. is the holding company of mPathix Health, Inc. The company is focused on the development, production, and distribution of multi-modal pain management and Central Nervous System related solutions. It develops pain management products using a modality agnostic, virtual operating model. The company is developing a product designed to address the unmet needs of patients who seek alternatives to traditional pain medications and interventions or adjunctive therapies to their current treatment regimen.
Executives
Bin Wang director 112 RICO DR. NORTH, MORGANVILLE NJ 07751